期刊文献+

西格列汀二甲双胍片(Ⅱ)治疗2型糖尿病的疗效观察 被引量:4

Clinical Observation of Sitagliptin Phosphate/Metformin Hydrochloride Tablets (Ⅱ) in Treating Type 2 Diabetes Mellitus
下载PDF
导出
摘要 目的:探讨西格列汀二甲双胍片(Ⅱ)治疗2型糖尿病的疗效。方法:本院164例2型糖尿病患者,数字随机分为两组,观察组82例采取西格列汀二甲双胍片(Ⅱ)治疗,对照组82例采取盐酸二甲双胍片治疗,比较两组效果。结果:研究组治疗有效率高于对照组(93.90%vs 82.93%,P<0.05)。治疗后研究组餐后2h血糖(2hPBG)、空腹血糖(FPG)、甘油三酯(TG)、低密度脂蛋白胆固醇(LDL-C)优于对照组(P<0.05)。结论:对于2型糖尿病患者,采取西格列汀二甲双胍片(Ⅱ)治疗,效果显著。 Objective:To explore the curative effect of siglitine metformin(Ⅱ)on type 2 diabetes mellitus.Method:164 patients with type 2 diabetes were randomly divided into two groups.82 patients in the observation group were treated with siglitine metformin tablets(Ⅱ),and 82 patients in the control group were treated with metformin hydrochloride tablets,and the effects of the two groups were compared.Result:The treatment efficiency of the study group was higher than that of the control group(93.90%vs 82.93%,P<0.05).After treatment,2h postprandial blood glucose(2hPBG)fasting blood glucose(FPG)triglyceride(TG)low-density lipoprotein cholesterol(LDL-C)in the study group was superior to the control group(P<0.05).Conclusion:In patients with type 2 diabetes, siglitine metformin tablets (Ⅱ) was used for treatment, with significant effect.
作者 张春玲 Zhang Chunling(Altay Region Maternal and Child Health Hospital,836500)
出处 《黑龙江医药》 CAS 2019年第5期1095-1097,共3页 Heilongjiang Medicine journal
关键词 2型糖尿病 西格列汀二甲双胍片(Ⅱ) 盐酸二甲双胍片 Type 2 diabetes Sitagliptin Phosphate/metformin Hydrochloride Tablets(Ⅱ) Metformin Hydrochloride Tablets
  • 相关文献

参考文献8

二级参考文献54

  • 1顾海,李洪超.药物经济学成本-效果分析应用的相关问题探讨[J].中国药房,2004,15(11):674-676. 被引量:122
  • 2董慧,陆付耳,徐丽君,王开富,邹欣.不同中医证型的初诊2型糖尿病患者临床特征分析[J].中国中西医结合杂志,2004,24(10):904-905. 被引量:2
  • 3刘瑛,王萌,薛洁.不同中医证型的2型糖尿病患者临床特征分析[J].新疆中医药,2007,25(1):25-26. 被引量:6
  • 4INTERNATIONAL DIABETES FEDERATION.Diabetes Atlas 6th Edition,2013 Update.
  • 5American Association of Clinical Endocrinologists.Comprehensive Diabetes Management Algorithm 2013.published in Endocr Pract.2013,19(Suppl 1):1-48.
  • 6International Diabetes Federation.Global Guideline for Type 2 Diabetes,2012.
  • 7CHARBONNEL B,KARASIK A,LIU J,et al.Efficacy and safety of the dipeptide peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone[J].Diabetes Care,2006,29(12):2638-43.
  • 8DORMANDY J,BHATTACHARYA M,VAN TROOSTENBURG DE BRUYN AR,et al.Safety and tolerability of pioglitazone in high-risk patients with type 2 diabetes:an overview of data from PROactive[J].Drug saf,2009,32(3):187-202.
  • 9DEROSA G,RAGONESI PD,FOGARI E,et al.Sitagliptin added to previously taken antidiadetic agents on insulin resistance and lipid profile:a 2-year study evaluation[J].Fundam Clin Pharmacol,2012,2:10-11.
  • 10MONAMI M,IACOMELLI I,MARCHIONNI N,et al.Dipeptydil peptidase-4 inhibitors in type 2 diabet:a meta-analysis of randomized clinical triats[J].Nutr Metab Cardiovasc Dis,2010,20:224-235.

共引文献44

同被引文献49

引证文献4

二级引证文献5

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部